We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bharat Biotech Unveils High Interim Efficacy Rate for COVID-19 Vaccine
Bharat Biotech Unveils High Interim Efficacy Rate for COVID-19 Vaccine
Indian drugmaker Bharat Biotech has announced that its COVID-19 vaccine candidate, Covaxin (BBV152), proved to be 80.6 percent effective in the initial interim analysis of its late-stage clinical trials.